logo
Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo02-05-2025
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum's 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price of $3.33 per share, equal to the per share closing price of Adverum's common stock as reported by Nasdaq on the grant date of May 1, 2025. The stock options vest over four years, with 25% vesting on the first anniversary of the applicable vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Adverum through the applicable vesting dates. The restricted stock units vest over three years, with one third (1/3rd) vesting on each anniversary of the applicable vesting commencement date, subject to the employee being continuously employed by Adverum through the applicable vesting dates. The awards are subject to the terms and conditions of Adverum's 2017 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians' offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Corporate and Investor Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
Media:Jason Awe, Ph.D.Executive Director, Corporate CommunicationsEmail: jawe@adverum.comSign in to access your portfolio
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nvidia's $4.5 Trillion Market Cap Tops All 2,000 Russell Small-Caps Combined
Nvidia's $4.5 Trillion Market Cap Tops All 2,000 Russell Small-Caps Combined

Yahoo

time11 minutes ago

  • Yahoo

Nvidia's $4.5 Trillion Market Cap Tops All 2,000 Russell Small-Caps Combined

Nvidia (NASDAQ:NVDA) just hit another mind-bending milestone. The chip giant's market cap has swelled to $4.5 trillion, putting it $1.5 trillion above the entire Russell 2000 index. That means one company is now worth more than 2,000 small U.S. firms combined. Warning! GuruFocus has detected 5 Warning Signs with NVDA. It's a snapshot of where the market's energy really is. While small-caps grind along, mega-cap tech led by Nvidia keeps sucking up the oxygen. The comparison shows how lopsided the rally has become, with AI demand fueling outsized gains for a handful of giants. Nvidia isn't just dominating in price. It's woven into the core of global investing. The stock sits inside 667 ETFs, which together control nearly 3.6 billion shares. Whether through passive funds or active bets, chances are, most investors already own a slice of Nvidia. That reach makes every tick of its stock ripple across portfolios worldwide. Nvidia isn't just a chipmaker anymore it's become a market-moving force, one whose valuation now rivals entire economies. This article first appeared on GuruFocus. Sign in to access your portfolio

Paramount Skydance (PSKY) Jumps 30% on Meme Rally
Paramount Skydance (PSKY) Jumps 30% on Meme Rally

Yahoo

time11 minutes ago

  • Yahoo

Paramount Skydance (PSKY) Jumps 30% on Meme Rally

We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the last week's top performers. Paramount Skydance surged by 30.5 percent week-on-week, having performed a 'meme' rally during the week, according to a stock market expert. In a social media post last week, Mad Money host and former hedge fund manager Jim Cramer regarded Paramount Skydance Corp. (NASDAQ:PSKY) as a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments to perk up buying. However, investors may have snapped up shares after it bagged a $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. Photo by Kosta Bratsos on Unsplash As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will remove the pay-per-view model in favor of making the events available at no additional cost to subscribers of Paramount+ in the US. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .

Palo Alto Networks (PANW) Rating Reaffirmed: Cantor Fitzgerald Sees $223 Target Ahead of Earnings
Palo Alto Networks (PANW) Rating Reaffirmed: Cantor Fitzgerald Sees $223 Target Ahead of Earnings

Yahoo

time11 minutes ago

  • Yahoo

Palo Alto Networks (PANW) Rating Reaffirmed: Cantor Fitzgerald Sees $223 Target Ahead of Earnings

Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the . On August 15, Cantor Fitzgerald reiterated its 'Overweight' rating on the stock with a $223.00 price target. The rating update comes ahead of the company's fiscal fourth-quarter 2025 results due on August 18 after markets close. Cantor anticipates strong execution, large deal activity, and Palo Alto's platformization to drive the company's F4Q25 results. However, revenue guidance may come in lower due to short-term platformization impacts. 'We maintain our Overweight rating and reiterate our 12-month PT of $223. We anticipate strong execution, large deal activity, and platformization to drive solid F4Q25 results across KPIs. While bookings trends likely remain robust and supportive of current FY26 expectations for RPO and NGARR, we would not be surprised to see FY26 revenue guidance light of expectations, reflecting the initial revenue recognition headwinds on platformization deals that begins to normalize in FY27 and FY28." Palo Alto Networks, Inc. (NASDAQ:PANW) is a leader in AI-powered cybersecurity. While we acknowledge the potential of PANW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store